Suppliers / Regis Technologies

Regis Technologies

United States Updated 9 July 2026

Regis Technologies is an API manufacturer based in United States. It holds 4 active US drug master files across a filed portfolio of 3 molecules. Its most recent recorded inspection, by US FDA, closed on 16 November 2022 as VAI.

4
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
7 of 7 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 16 November 2022 VAI US FDA
  • 23 April 2019 NAI US FDA
  • 15 August 2016 NAI US FDA
  • 17 December 2013 NAI US FDA
  • 30 March 2012 NAI US FDA
  • 8 March 2011 VAI US FDA
  • 8 May 2009 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Morton Grove, United States 1416120

What they file, and where

Molecule Regulators Docs
Dalfampridine SFDA (Saudi Arabia), US FDA 3
Acetazolamide US FDA 2
Bromfenc SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Acetazolamide API Dalfampridine API

Comparing suppliers?

Choose your molecules and target markets. Regis Technologies comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 16 November 2022.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability